Triad Rx

2 telehealth providers in the Telehealth Ledger directory name Triad Rx as a fulfillment pharmacy on their own public pages: Embody and SnagRX. Each name below links to that provider's profile, where the pharmacy statement sits beside its dated source.

Embody's pharmacy disclosure, as recorded in its dossier: Embody names these partner pharmacies; assignment varies. Quoted from Embody's homepage: "Red Rock Compounding Pharmacy — St. George, UT; Health Warehouse — Florence, KY".

Naming a pharmacy does not mean every prescription goes there. Most telehealth services list several partners and route each order by medication, state licensure, and stock, so the pharmacy on your label can differ from the marketing page. The vial label is the authoritative record of who compounded and dispensed it.

• Embody →
• SnagRX →

Triad Rx is recorded here as a 503A compounding pharmacy. FDA's February 2019 warning letter evaluated the firm against the conditions of section 503A and its December 2022 Form 483 lists it as a non-sterile drug producer; it does not appear on FDA's registered outsourcing facility list (checked 2026-09-10). Its own site makes no 503A or 503B statement.

A 503A pharmacy compounds a patient-specific prescription and is licensed and inspected primarily by its state board of pharmacy; it does not register with FDA as an outsourcing facility and is not required to follow federal current good manufacturing practice (CGMP). Compounded semaglutide or tirzepatide from a 503A pharmacy is not an FDA-approved product, and the beyond-use date on the label comes from the pharmacy's own stability practice under USP standards rather than from an approved drug application.

5 public regulatory records for Triad Rx were found in the databases checked on 10 September 2026. Each is summarized neutrally below, in date order, with a link to the primary document. A record is a fact about a filing, not a judgment about current practice: a Form 483 lists an inspector's observations, a warning letter states FDA's position after review, and a close-out letter records that FDA considers the letter's issues addressed.

Databases checked: FDA registered outsourcing facilities list (updated 2026-09-08) (no record found); FDA compounding inspections, recalls, and other actions (record found).

If a new letter, action, or recall appears, it is added with its date and primary link and earlier summaries are not rewritten.

1. 21 July 2017 · FDA: Form FDA 483. FDA issued an inspectional observation list after a July 2017 inspection. Primary document ↗
2. 5 February 2019 · FDA: Warning letter MARCS-CMS 569659. FDA cited compounding that did not meet the conditions of section 503A, sterile products prepared under insanitary conditions, and misbranding. Primary document ↗
3. 8 December 2022 · FDA: Form FDA 483. The single observation concerned cleaning of work surfaces and utensils between hazardous hormone-cream preparations. Primary document ↗
4. 3 May 2023 · FDA: Warning letter close-out. FDA acknowledged that the firm no longer produces sterile drug products and stated it appeared to have adequately addressed the violations in the 2019 letter. Primary document ↗
5. 3 May 2023 · FDA: State referral letter to the Alabama Board of Pharmacy. FDA referred the 2022 findings to the Alabama board, described them as readily correctable, and stated it did not intend further action at that time. Primary document ↗

• FDA registered outsourcing facilities list (updated 2026-09-08) ↗
• FDA compounding inspections, recalls, and other actions ↗

A public Alabama board of pharmacy license record for Triad Rx, Inc. was not found through the lookups tried, or the lookup requires an interactive search that cannot be linked directly. That does not mean the pharmacy is unlicensed; most state verification portals do not expose stable URLs. Non-resident licenses in the states it ships to are held in each of those states' own systems.

No NABP accreditation (PCAB, Digital Pharmacy, or similar) was found listed for this pharmacy on the dates checked. Accreditation is voluntary and its absence is not a finding.

Triad Rx does not publish a beyond-use date policy, stability study, or testing statement on the public pages checked. Many compounding pharmacies share this only with the prescribing provider or on request, so "not found" describes the public website, not the pharmacy's records.

A beyond-use date (BUD) is the date after which a compounded preparation must not be used; the pharmacy assigns it under USP <797> sterile compounding standards and prints it on the dispensing label. It is not the same as a manufacturer's expiration date on a brand pen. Follow the storage and BUD printed on your pharmacy label; if a vial arrives without one, ask the dispensing pharmacy before use.

Triad Rx does not publish a patient-facing shipping or cold-chain statement on the pages checked, so the shipping promises below come from the telehealth providers that route orders to it.

Provider shipping claims: Embody says Medication, supplies, and standard shipping are included in the published GLP-1 totals. SnagRX says The site describes expedited temperature-controlled weekday shipping after approval.

Compounded semaglutide and tirzepatide ship refrigerated: an insulated box with cold packs, usually by an overnight or two-day carrier service on weekdays so a package is never in transit over a weekend. On arrival, put the vial in the refrigerator, check the label for the BUD and storage line, and contact the pharmacy if the cold pack is fully thawed or the vial is warm.